JP7592220B2 - アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用 - Google Patents

アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用 Download PDF

Info

Publication number
JP7592220B2
JP7592220B2 JP2024518681A JP2024518681A JP7592220B2 JP 7592220 B2 JP7592220 B2 JP 7592220B2 JP 2024518681 A JP2024518681 A JP 2024518681A JP 2024518681 A JP2024518681 A JP 2024518681A JP 7592220 B2 JP7592220 B2 JP 7592220B2
Authority
JP
Japan
Prior art keywords
alkyl
equiv
mmol
methyl
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024518681A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535393A (ja
Inventor
ロバート エル． ホフマン，
チン ドン，
スティーブン ダブリュー． カルドー，
リニー トルゾス，
ポリノ ジンジョ ヴァ，
Original Assignee
シンセラ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンセラ， インコーポレイテッド filed Critical シンセラ， インコーポレイテッド
Publication of JP2024535393A publication Critical patent/JP2024535393A/ja
Priority to JP2024201685A priority Critical patent/JP2025024130A/ja
Application granted granted Critical
Publication of JP7592220B2 publication Critical patent/JP7592220B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024518681A 2021-10-01 2022-09-30 アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用 Active JP7592220B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024201685A JP2025024130A (ja) 2021-10-01 2024-11-19 アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163251469P 2021-10-01 2021-10-01
US63/251,469 2021-10-01
US202263339597P 2022-05-09 2022-05-09
US63/339,597 2022-05-09
US202263402835P 2022-08-31 2022-08-31
US63/402,835 2022-08-31
PCT/US2022/045415 WO2023056039A1 (en) 2021-10-01 2022-09-30 Azetidine and pyrrolidine parp1 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024201685A Division JP2025024130A (ja) 2021-10-01 2024-11-19 アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用

Publications (2)

Publication Number Publication Date
JP2024535393A JP2024535393A (ja) 2024-09-30
JP7592220B2 true JP7592220B2 (ja) 2024-11-29

Family

ID=85783565

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024518681A Active JP7592220B2 (ja) 2021-10-01 2022-09-30 アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用
JP2024201685A Pending JP2025024130A (ja) 2021-10-01 2024-11-19 アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024201685A Pending JP2025024130A (ja) 2021-10-01 2024-11-19 アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用

Country Status (17)

Country Link
US (2) US20230159525A1 (https=)
EP (1) EP4408420A4 (https=)
JP (2) JP7592220B2 (https=)
KR (2) KR20250145706A (https=)
CN (2) CN120058698A (https=)
AU (2) AU2022356286B2 (https=)
CA (1) CA3232775A1 (https=)
CL (2) CL2024000877A1 (https=)
CO (1) CO2024003949A2 (https=)
CR (1) CR20240144A (https=)
DO (1) DOP2024000060A (https=)
IL (2) IL318196A (https=)
MX (2) MX2024003922A (https=)
PE (1) PE20241129A1 (https=)
TW (2) TWI876212B (https=)
WO (1) WO2023056039A1 (https=)
ZA (1) ZA202404648B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
AU2023209820B2 (en) 2022-01-21 2024-10-10 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
FI4497438T3 (fi) 2022-04-28 2025-10-20 Xinthera Inc Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
EP4514795A4 (en) * 2022-04-28 2025-12-31 Ningbo Newbay Tech Development Co Ltd COMPOUNDS USED AS PARP1 INHIBITORS
CN119255995A (zh) * 2022-05-25 2025-01-03 西藏海思科制药有限公司 双环衍生物parp抑制剂及其用途
TW202416977A (zh) * 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
CN121698877A (zh) * 2022-11-10 2026-03-20 正大天晴药业集团股份有限公司 稠合双环化合物
JP2025538192A (ja) * 2022-11-10 2025-11-26 上海海和薬物研究開発股▲ふん▼有限公司 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用
CN120882710A (zh) * 2023-03-24 2025-10-31 新特拉有限公司 氮杂环丁烷parp1抑制剂的结晶形式
WO2024227026A1 (en) * 2023-04-28 2024-10-31 Synnovation Therapeutics, Inc. Heterocyclic compounds as parp1 inhibitors
EP4729514A1 (en) 2023-06-14 2026-04-22 Haisco Pharmaceutical Group Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
TW202535877A (zh) * 2023-11-01 2025-09-16 大陸商正大天晴藥業集團股份有限公司 含有稠合雙環的化合物、藥物組合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500758A (ja) 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
JP2018523679A (ja) 2015-08-17 2018-08-23 ルピン・リミテッド Ｐａｒｐ阻害剤としてのヘテロアリール誘導体
JP2022541483A (ja) 2019-07-19 2022-09-26 アストラゼネカ・アクチエボラーグ Ｐａｒｐ１阻害薬
JP2023506368A (ja) 2019-10-30 2023-02-16 ディグムバイオ．インコーポレイテッド イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ（ａｄｐ－リボース）ポリメラーゼ－１（ｐａｒｐ－１）関連疾患の予防又は治療用薬学的組成物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
WO2009076512A1 (en) 2007-12-11 2009-06-18 Epix Delaware, Inc. Carboxamidξ compounds and their use as chemokine receptor agonists
KR101779137B1 (ko) 2009-01-23 2017-09-18 다케다 야쿠힌 고교 가부시키가이샤 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
HUE051078T2 (hu) 2012-10-26 2021-03-01 Nerviano Medical Sciences Srl 4-karboxamido-izoindolinone származék mint szelektív parp-1 inhibitor
JP2017508798A (ja) 2014-03-07 2017-03-30 ザ ジョンズ ホプキンス ユニバーシティ ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤
CN105753814A (zh) 2015-01-01 2016-07-13 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
PH12017502228B1 (en) 2015-06-09 2022-08-03 Onconic Therapeutics Inc Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
IL283127B1 (en) 2018-11-14 2026-02-01 Smilebiotek Zhuhai Ltd Animal-based models, scanning methods, and methods of treating intraocular diseases or disorders
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202309025A (zh) 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
CA3213029A1 (en) 2021-04-22 2022-10-27 Yuli Xie Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
WO2022222965A1 (zh) 2021-04-23 2022-10-27 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
WO2022223025A1 (zh) 2021-04-23 2022-10-27 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
TW202304911A (zh) 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2022222966A1 (zh) 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
WO2022228387A1 (en) * 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
EP4349836A4 (en) 2021-05-24 2024-10-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATION IN DRUGS
CN115403595A (zh) 2021-05-27 2022-11-29 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
JP2024522736A (ja) 2021-06-16 2024-06-21 リペア セラピューティクス インコーポレイテッド がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用
AU2022334408A1 (en) 2021-08-27 2024-02-15 Impact Therapeutics (Shanghai), Inc. Substituted tricyclic compounds as parp inhibitors and use thereof
CN118119618A (zh) 2021-09-09 2024-05-31 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
WO2023046158A1 (zh) 2021-09-26 2023-03-30 张文燕 氮杂喹啉酮类化合物及其医药用途
WO2023046149A1 (zh) 2021-09-26 2023-03-30 张文燕 喹喔啉类化合物及其医药用途
US20240391937A1 (en) 2021-09-30 2024-11-28 Xizang Haisco Pharmaceutical Co., Ltd. Bicyclic derivative parp inhibitor and use thereof
WO2023051812A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 含氮杂环衍生物parp抑制剂及其用途
WO2023051716A1 (zh) 2021-09-30 2023-04-06 海思科医药集团股份有限公司 杂芳基衍生物parp抑制剂及其用途
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
WO2023061406A1 (zh) 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
JP7762306B2 (ja) 2021-11-19 2025-10-29 康百達（四川）生物医薬科技有限公司 選択的ｐａｒｐ１阻害剤およびその用途
CN116143776A (zh) 2021-11-22 2023-05-23 南京圣和药业股份有限公司 Parp1抑制剂及其应用
CA3241338A1 (en) 2021-12-17 2023-06-22 Yongqi Deng Parp inhibitor, pharmaceutical composition comprising same, and use thereof
WO2023133413A1 (en) 2022-01-07 2023-07-13 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023138541A1 (zh) 2022-01-20 2023-07-27 微境生物医药科技(上海)有限公司 吡啶酰胺类parp抑制剂、及其制备方法和医药用途
AU2023209820B2 (en) 2022-01-21 2024-10-10 Xinthera, Inc. Parp1 inhibitors and uses thereof
CN116535401A (zh) 2022-01-25 2023-08-04 南京圣和药业股份有限公司 新的parp1抑制剂及其应用
WO2023143236A1 (zh) 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
WO2023147009A1 (en) 2022-01-27 2023-08-03 The Johns Hopkins University Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks
US20260098024A1 (en) 2022-01-27 2026-04-09 Xinthera, Inc. Parp1 inhibitors and uses thereof
US20250177359A1 (en) 2022-01-28 2025-06-05 Oulun Yliopisto Compounds for use in the treatment of cancer and inflammatory conditions
KR20230116457A (ko) 2022-01-28 2023-08-04 경북대학교 산학협력단 작약 추출물을 포함하는 만성폐쇄성폐질환 예방 또는 치료용 약학적 조성물
WO2023146960A1 (en) 2022-01-28 2023-08-03 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR20240149429A (ko) 2022-02-16 2024-10-14 듀크 스트리트 바이오 리미티드 약학적 화합물
CN115232129B (zh) 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500758A (ja) 2007-10-26 2011-01-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキノリノン誘導体
JP2018523679A (ja) 2015-08-17 2018-08-23 ルピン・リミテッド Ｐａｒｐ阻害剤としてのヘテロアリール誘導体
JP2022541483A (ja) 2019-07-19 2022-09-26 アストラゼネカ・アクチエボラーグ Ｐａｒｐ１阻害薬
JP2023506368A (ja) 2019-10-30 2023-02-16 ディグムバイオ．インコーポレイテッド イソキノリノン誘導体、その製造方法及びそれを有効成分として含有するポリ（ａｄｐ－リボース）ポリメラーゼ－１（ｐａｒｐ－１）関連疾患の予防又は治療用薬学的組成物

Also Published As

Publication number Publication date
KR20240069791A (ko) 2024-05-20
IL318196A (en) 2025-03-01
CO2024003949A2 (es) 2024-04-18
EP4408420A1 (en) 2024-08-07
TW202322807A (zh) 2023-06-16
CN120058698A (zh) 2025-05-30
US20230203033A1 (en) 2023-06-29
WO2023056039A1 (en) 2023-04-06
KR20250145706A (ko) 2025-10-13
ZA202404648B (en) 2026-01-28
DOP2024000060A (es) 2024-05-15
JP2024535393A (ja) 2024-09-30
TW202542152A (zh) 2025-11-01
AU2025200139A1 (en) 2025-01-30
AU2022356286B2 (en) 2024-10-10
CR20240144A (es) 2024-05-24
NZ810237A (en) 2024-10-25
AU2022356286A1 (en) 2024-05-16
TWI876212B (zh) 2025-03-11
IL311376B2 (en) 2025-06-01
EP4408420A4 (en) 2025-04-02
KR102867210B1 (ko) 2025-10-14
IL311376A (en) 2024-05-01
PE20241129A1 (es) 2024-05-24
MX2024012801A (es) 2024-11-08
IL311376B1 (en) 2025-02-01
CL2024000877A1 (es) 2024-09-27
CN118019532B (zh) 2025-03-18
US20230159525A1 (en) 2023-05-25
US11802128B2 (en) 2023-10-31
JP2025024130A (ja) 2025-02-19
CL2025000629A1 (es) 2025-08-08
CA3232775A1 (en) 2023-04-06
CN118019532A (zh) 2024-05-10
MX2024003922A (es) 2024-04-22

Similar Documents

Publication Publication Date Title
JP7592220B2 (ja) アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用
US11591331B2 (en) PARP1 inhibitors and uses thereof
JP7607841B1 (ja) Ｐａｒｐ１阻害薬及びその使用
JP7728989B2 (ja) 三環式ｐａｒｐ１阻害剤及びその使用
JP2025503116A (ja) Ｐａｒｐ１阻害薬及びその使用
EA049024B1 (ru) Ингибиторы parp1 на основе азетидина и пирролидина и их применение
BR122025000034B1 (pt) Inibidores de azetidina e pirrolidina parp1, composições que os compreendem, e usos dos mesmos
BR112024005058B1 (pt) Inibidores de azetidina e pirrolidina parp1 e composições que os compreendem
BR122025000034A2 (pt) Inibidores de azetidina e pirrolidina parp1, composições que os compreendem, e usos dos mesmos
HK40110567A (zh) 氮杂环丁烷和吡咯烷parp1抑制剂及其用途
HK40110567B (zh) 氮杂环丁烷和吡咯烷parp1抑制剂及其用途
HK40126682A (zh) 氮杂环丁烷和吡咯烷parp1抑制剂及其用途
EA051378B1 (ru) Ингибиторы parp1 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241119

R150 Certificate of patent or registration of utility model

Ref document number: 7592220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150